Tech Company Financing Transactions
MinervaX Funding Round
On 12/15/2022, MinervaX raised $76.3 million in funding from Pureos Bioventures, Trill Impact Ventures and Adjuvant Capital.
Transaction Overview
Company Name
Announced On
12/15/2022
Transaction Type
Venture Equity
Amount
$76,310,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to advance the late-stage development of its GBS vaccine candidate in preparation for a Phase 3 clinical trial.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Ole Maaløes Vej 3
Copenhagen N, DK-2200
DK
Copenhagen N, DK-2200
DK
Phone
Undisclosed
Website
Email Address
Overview
MinervaX is pursuing the development of a maternal vaccine for the prevention of adverse pregnancy outcomes and life-threating infections caused by Group B streptococcus (GBS). The vaccine is based on adjuvanted proteins antigens covering close to 100% of clinical GBS isolates.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Per Fischer
Browse more venture capital transactions:
Prev: 12/15/2022: July venture capital transaction
Next: 12/15/2022: Spaceport venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs